ANAPTYSBIO, INC
AnaptysBio, Inc. (NASDAQ: ANAB) is a clinical-stage biotechnology company focused on developing innovative immunology therapeutics for autoimmune and inflammatory diseases. The company's website is www.anaptysbio.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What ANAPTYSBIO, INC does
In the company’s own words
AnaptysBio, Inc. (NASDAQ: ANAB) is a clinical-stage biotechnology company focused on developing innovative immunology therapeutics for autoimmune and inflammatory diseases. The company's website is www.anaptysbio.com.
The company operates through two primary business segments: wholly owned clinical-stage product candidates and collaborative programs generating milestone and royalty revenue. AnaptysBio's internal pipeline includes rosnilimab, a selective pathogenic T cell depleter currently in Phase 2b development for moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist in Phase 1b trials for celiac disease and eosinophilic esophagitis; and ANB101, a BDCA2 modulator in Phase 1a development for autoimmune and inflammatory diseases.
The company generates revenue through financial collaborations with major pharmaceutical partners. Under its immuno-oncology collaboration with GSK, AnaptysBio receives milestone payments and tiered royalties on sales of Jemperli (dostarlimab), a PD-1 antagonist approved by the FDA for multiple endometrial cancer indications. GSK reported $1.1 billion in Jemperli sales for 2025, representing greater than 80% growth from the prior year. Additionally, AnaptysBio entered into an exclusive license agreement with Vanda Pharmaceuticals in January 2025 for imsidolimab, an IL-36R antagonist for generalized pustular psoriasis, receiving an upfront payment of $10 million plus eligibility for royalties and regulatory milestones.
In September 2025, AnaptysBio announced plans to separate its operations into two independent, publicly traded companies, with separation expected to complete in the second quarter of 2026. One entity will manage the financial collaborations with GSK and Vanda, while the other will focus on developing and commercializing the company's clinical-stage therapeutics portfolio.
The company's intellectual property portfolio comprises approximately 96 issued patents and 120 pending patent applications as of December 31, 2025, covering product candidates, novel biological discoveries, and antibody discovery technology. AnaptysBio relies on third-party manufacturers for cGMP-compliant production of clinical trial materials and maintains internal non-cGMP manufacturing capabilities for preclinical research and development activities.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- SAN DIEGO, CA
- Fiscal year end
- June
- CIK
- 1370053
- SIC
- 2834
Financial performance, year by year
Fiscal 2017–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns ANAPTYSBIO, INC — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · ANAPTYSBIO, INC’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do ANAPTYSBIO, INC and its peers compare on margins and cash generation over ten years?”
- “Where did five years of ANAPTYSBIO, INC's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in ANAPTYSBIO, INC's last four quarterly filings that the numbers alone won't show?”